Semaglutide may aid liver

Semaglutide, the drug in Ozempic and Wegovy, appears to help the liver directly — not just by helping patients lose weight. (utoronto.ca) The finding comes from researchers at Sinai Health and the University of Toronto, who reported on April 15 that semaglutide improved liver function by acting on specific liver cells in mouse models of metabolic dysfunction-associated steatohepatitis, or MASH. The paper was published in *Cell Metabolism*. (sinaihealth.ca, cell.com) MASH is an advanced form of fatty liver disease: fat builds up in the liver, inflammation follows, and scar tissue can form until some patients develop cirrhosis or liver failure. University of Toronto said the condition affects about 25% of Canadian adults, while the U.S. Food and Drug Administration has said MASH affects about 6% of U.S. adults. (utoronto.ca, fda.gov) For years, doctors saw liver inflammation, scarring and enzyme levels improve in some semaglutide patients even when weight loss was modest. Daniel Drucker, the senior investigator who led the study, said that mismatch is what pushed researchers to look for a direct liver effect. (utoronto.ca) The team said semaglutide’s key target was a small group of blood-vessel cells inside the liver called liver sinusoidal endothelial cells. Those cells make up only about 3% of liver cell volume, but the researchers said they were the main driver of the drug’s liver benefit. (sinaihealth.ca, cell.com) The study also identified semaglutide receptors on immune T cells in the liver, which helped overturn an older assumption that liver tissue had no direct route for the drug to act there. In the researchers’ model, semaglutide reduced inflammation and scarring through a liver signaling network that did not depend on weight loss. (sinaihealth.ca, cell.com) That mechanism matters because semaglutide is already being used in liver disease. The FDA approved Wegovy in August 2025 for adults with noncirrhotic MASH and moderate-to-advanced fibrosis under accelerated approval. (fda.gov, accessdata.fda.gov) The new paper does not show, by itself, that every liver benefit in people comes from the same pathway seen in mice. But it gives researchers a clearer biological explanation for why semaglutide has shown liver effects in trials even when the scale changed less than expected. (cell.com, utoronto.ca) The next step is not a new hype cycle so much as a narrower question: which patients get the liver benefit, and how much of it comes from this direct pathway. The Toronto group’s answer, for now, is that semaglutide seems to be doing more in the liver than trimming body weight alone. (sinaihealth.ca, utoronto.ca)